Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.

MLA

Houot, Roch, et al. “Author Correction: Axicabtagene Ciloleucel as Second-Line Therapy in Large B Cell Lymphoma Ineligible for Autologous Stem Cell Transplantation: A Phase 2 Trial.” Nature Medicine, vol. 30, no. 7, July 2024, p. 2089. EBSCOhost, https://doi.org/10.1038/s41591-024-03053-z.

APA

Houot, R., Bachy, E., Cartron, G., Gros, F.-X., Morschhauser, F., Oberic, L., Gastinne, T., Feugier, P., Duléry, R., Thieblemont, C., Joris, M., Jardin, F., Choquet, S., Casasnovas, O., Brisou, G., Cheminant, M., Bay, J.-O., Gutierrez, F. L., Menard, C., … Lemonnier, F. (2024). Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nature Medicine, 30(7), 2089. https://doi.org/10.1038/s41591-024-03053-z

Chicago

Houot, Roch, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, Lucie Oberic, Thomas Gastinne, et al. 2024. “Author Correction: Axicabtagene Ciloleucel as Second-Line Therapy in Large B Cell Lymphoma Ineligible for Autologous Stem Cell Transplantation: A Phase 2 Trial.” Nature Medicine 30 (7): 2089. doi:10.1038/s41591-024-03053-z.